KPV is in the July 2026 FDA peptide discussion queue.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Refresh after the meeting record or final materials are available.
Research peptide
KPV
KPV is a peptide topic appearing in online wellness and research discussions. This page tracks the public source record and keeps claims separated from treatment language.
Regulatory watch
Last reviewed 2026-07-03
Next review 2026-07-24
Evidence snapshot
Use this page as a watchlist entry until the FDA advisory committee materials and meeting record can be reviewed.
Scheduled for FDA advisory committee discussion in July 2026.
Online claims should be treated as source-discovery signals, not proof.
Needs a post-meeting refresh before being expanded.
Tracked claims
Preclinical studies report that KPV has anti-inflammatory effects in animal models, but no human clinical trials have been published.
Evidence level: Peer reviewed
Sources: PubMed / NCBI
KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH. The evidence base is entirely preclinical; do not frame as a treatment for inflammatory conditions.
KPV is discussed online as an oral anti-inflammatory peptide despite the lack of human clinical evidence.
Evidence level: Community discussion
Sources: PubMed / NCBI, U.S. Food and Drug Administration
Track community claims as source-discovery signals. The FDA bulk risk list applies to compounded peptide products marketed beyond research use.
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate KPV claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
KPV and alpha-MSH-derived tripeptides: anti-inflammatory activity in preclinical models
Preclinical studies of KPV (Lys-Pro-Val), a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH), showing anti-inflammatory effects in animal models of intestinal and systemic inflammation. No human clinical trials have been published.
Related compounds
BPC-157
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watchDSIP
DSIP appears in online sleep and recovery discussions. This page tracks the topic as a source-backed index entry pending...
Regulatory watchEpitalon
Epitalon is often discussed in longevity-oriented peptide content. The page starts as a regulatory watch entry and shoul...
Regulatory watchSemax
Semax is often discussed online in cognitive and performance contexts. The index treats it as a source-backed watch item...
Regulatory watchStay informed